VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 111 filers reported holding VANDA PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $9,869,000 | -81.5% | 430,000 | -84.6% | 0.45% | -77.9% |
| Q2 2018 | $53,344,000 | +14.1% | 2,800,191 | +0.9% | 2.05% | -8.0% |
| Q1 2018 | $46,762,000 | +118.4% | 2,775,191 | +97.0% | 2.23% | +60.9% |
| Q4 2017 | $21,416,000 | +21.1% | 1,408,946 | +42.6% | 1.39% | +1.2% |
| Q3 2017 | $17,690,000 | +20.3% | 988,270 | +9.5% | 1.37% | -26.1% |
| Q2 2017 | $14,705,000 | +70.2% | 902,146 | +46.2% | 1.86% | +68.2% |
| Q1 2017 | $8,641,000 | +42.0% | 617,200 | +61.8% | 1.10% | -10.2% |
| Q4 2016 | $6,084,000 | -55.8% | 381,466 | -53.9% | 1.23% | -49.2% |
| Q3 2016 | $13,773,000 | +73.5% | 827,693 | +16.6% | 2.42% | +37.0% |
| Q2 2016 | $7,940,000 | +11.1% | 709,579 | -17.0% | 1.76% | -29.2% |
| Q1 2016 | $7,144,000 | -39.1% | 854,579 | -32.2% | 2.49% | -38.4% |
| Q4 2015 | $11,738,000 | -51.0% | 1,260,809 | -40.7% | 4.04% | -35.1% |
| Q3 2015 | $23,965,000 | +31.3% | 2,124,593 | +47.7% | 6.23% | +23.9% |
| Q2 2015 | $18,257,000 | – | 1,438,693 | – | 5.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 4,525,476 | $74,263,000 | 4.09% |
| ARMISTICE CAPITAL, LLC | 2,828,000 | $46,407,000 | 2.68% |
| Birchview Capital, LP | 80,000 | $1,313,000 | 0.95% |
| GLOBEFLEX CAPITAL L P | 145,426 | $2,386,000 | 0.45% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 231,733 | $3,803,000 | 0.36% |
| 361 CAPITAL LLC | 77,630 | $1,274,000 | 0.35% |
| CADENCE CAPITAL MANAGEMENT LLC | 152,428 | $2,501,000 | 0.27% |
| BOOTHBAY FUND MANAGEMENT, LLC | 148,000 | $2,429,000 | 0.21% |
| EMERALD ADVISERS, LLC | 258,497 | $4,242,000 | 0.18% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 251,730 | $4,131,000 | 0.17% |